O drug-assisted treatment re-transmission of goodyin significantly improved the disease-free survival of patients with urethra skin cancer.

The interim analysis showed that CheckMate-274 reached the primary endpoint disease-free survival (DFS) in all random populations and PD-L1 expressions ≥1% of patients . . . Odevo has now been shown to have clinically significant efficacy in complementary treatments for three types of tumors, including bladder cancer, melanoma, esophageal cancer/ Gastroesophageal connectivity cancer Recently, Shishi Meishiguibao announced that a key Phase III clinical study called CheckMate -274 reached the primary study endpoint disease-free survival (DFS) in all randomized populations and tumor expression PD-L1 (programmed cell death licology 1) ≥1% of patients.
the study was designed to assess the efficacy and safety of Odivo (Navuliyu monoanti) in assisting the treatment of patients with high risk of recurrence of muscle-layer immersive urethroid cancer after surgery compared to placebo.
CheckMate-274 is the first and only Phase III clinical study to have been shown as an auxiliary treatment for these patients to reduce their risk of recurrence.
study, Odevo's safety characteristics were consistent with those previously reported in other solid tumor clinical studies.
About CheckMate -274 CheckMate -274 is a randomized, double-blind, multi-center Phase III clinical study designed to assess the efficacy and safety of Odivo's comparative placebo for patients with high risk of recurrence muscle-immersive urethroid cancer after surgery.
patients can be admitted to the group regardless of whether they have received new complementary treatment before surgery.
709 patients were randomly grouped at 1:1 for up to a year of Odivo or placebo treatment.
The main endpoints of this study were disease-free survival (DFS) in all randomized patients (i.e., intentional treatment populations) and tumor expression PD-L1≥1% of patients, and the key secondary endpoints include total lifetime (OS), non-urinal skin recurrence (NUTRFS), and disease-specific survival (DSS).
about urethra cancer Urine tract cancer usually originates from the internal cells of the bladder, is the world's 10th most common tumor.
about 550,000 new confirmed cases worldwide each year.
in addition to the bladder, urethra cancer can occur in other parts of the urinary system, including the ureter and kidneys.
most bladder cancers can be diagnosed at an early stage, but the recurrence and deterioration rates are high.
more than 50% of patients will face a recurrence of the disease after surgery.
for patients with advanced urethra skin cancer, poor first-line treatment remission is a major clinical challenge, and second-line treatment is still limited.
About Odivo Odivo was approved as the world's first PD-1 inhibitor in July 2014 and has been approved in 66 countries and territories for a total of 11 tumors1, covering lung, head and neck, stomach, esophageal, liver, kidney, colorectal, urethroid, melanoma, Hodgkin's lymphoma, thoracic tumors, and more than 590,000 patients worldwide.
Odivo is the first approved immuno-oncology drug approved in China, has been approved in China the following 3 adaptive disorders, in addition to other adaptation certificates have not been approved: 1) for the treatment of the skin growth factor recipient (EGFR) gene mutation negative and mesolytic lymphoma kinase (ALK) negative, previously received platinum-containing course chemotherapy after disease progression or insirability of local late-stage or metastatic non-small cell lung cancer (NSC) patients; 2) For patients with relapsed or metastatic head and neck squamous cell carcinoma (SCCHN) who have developed the disease during or after treatment with a platinum-containing program and who have positive expression of tumor PD-L1 (expression of PD-L1 tumor cells ≥1%); 3) for the treatment of patients with advanced or relapsed stomach or gastroesophageal connected adenocarcinoma who have previously received two or more systemic treatment options.
is the only PD-1 inhibitor developed directly by nobel laureates in physiology or medicine.
Meishi Shiguibao owns the exclusive use of Dr. Ben Yu's PD-1 patent.
Note 1: Odivo-based immunodiotherapy and immunotherapy.